Literature DB >> 12192322

Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.

Charles J Yeo1, John L Cameron, Keith D Lillemoe, Taylor A Sohn, Kurtis A Campbell, Patricia K Sauter, JoAnn Coleman, Ross A Abrams, Ralph H Hruban.   

Abstract

OBJECTIVE: To evaluate, in a prospective, randomized single-institution trial, the end points of operative morbidity, operative mortality, and survival in patients undergoing standard versus radical (extended) pancreaticoduodenectomy. SUMMARY BACKGROUND DATA: Numerous retrospective reports and a few prospective randomized trials have suggested that the performance of an extended lymphadenectomy in association with a pancreaticoduodenal resection may improve survival for patients with pancreatic and other periampullary adenocarcinomas.
METHODS: Between April 1996 and June 2001, 299 patients with periampullary adenocarcinoma were enrolled in a prospective, randomized single-institution trial. After intraoperative verification (by frozen section) of margin-negative resected periampullary adenocarcinoma, patients were randomized to either a standard pancreaticoduodenectomy (removing only the peripancreatic lymph nodes en bloc with the specimen) or a radical (extended) pancreaticoduodenectomy (standard resection plus distal gastrectomy and retroperitoneal lymphadenectomy). All pathology specimens were reviewed, fully categorized, and staged. The postoperative morbidity, mortality, and survival data were analyzed.
RESULTS: Of the 299 patients randomized, 5 (1.7%) were subsequently excluded because their final pathology failed to reveal periampullary adenocarcinoma, leaving 294 patients for analysis (146 standard vs. 148 radical). The two groups were statistically similar with regard to age (median 67 years) and gender (54% male). All the patients in the radical group underwent distal gastric resection, while 86% of the patients in the standard group underwent pylorus preservation ( <.0001). The mean operative time in the radical group was 6.4 hours, compared to 5.9 hours in the standard group ( =.002). There were no significant differences between the two groups with respect to intraoperative blood loss, transfusion requirements (median zero units), location of primary tumor (57% pancreatic, 22% ampullary, 17% distal bile duct, 3% duodenal), mean tumor size (2.6 cm), positive lymph node status (74%), or positive margin status on final permanent section (10%). The mean total number of lymph nodes resected was significantly higher in the radical group. Of the 148 patients in the radical group, only 15% (n = 22) had metastatic adenocarcinoma in the resected retroperitoneal lymph nodes, and none had retroperitoneal nodes as the only site of lymph node involvement. One patient in the radical group with negative pancreaticoduodenectomy specimen lymph nodes had a micrometastasis to one perigastric lymph node. There were six perioperative deaths (4%) in the standard group versus three perioperative deaths (2%) in the radical group ( = NS). The overall complication rates were 29% for the standard group versus 43% for the radical group ( =.01), with patients in the radical group having significantly higher rates of early delayed gastric emptying and pancreatic fistula and a significantly longer mean postoperative stay. With a mean patient follow-up of 24 months, there were no significant differences in 1-, 3-, or 5-year and median survival when comparing the standard and radical groups.
CONCLUSIONS: Radical (extended) pancreaticoduodenectomy can be performed with similar mortality but some increased morbidity compared to standard pancreaticoduodenectomy. The data to date fail to indicate that a survival benefit is derived from the addition of a distal gastrectomy and retroperitoneal lymphadenectomy to a pylorus-preserving pancreaticoduodenectomy.

Entities:  

Mesh:

Year:  2002        PMID: 12192322      PMCID: PMC1422589          DOI: 10.1097/00000658-200209000-00012

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  45 in total

1.  Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas.

Authors:  K Satake; H Nishiwaki; H Yokomatsu; Y Kawazoe; K Kim; A Haku; K Umeyama; I Miyazaki
Journal:  Surg Gynecol Obstet       Date:  1992-09

2.  Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Authors:  R A Abrams; L B Grochow; A Chakravarthy; T A Sohn; M L Zahurak; T L Haulk; S Ord; R H Hruban; K D Lillemoe; H A Pitt; J L Cameron; C J Yeo
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

3.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

4.  Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome.

Authors:  C J Yeo; J L Cameron; T A Sohn; J Coleman; P K Sauter; R H Hruban; H A Pitt; K D Lillemoe
Journal:  Ann Surg       Date:  1999-05       Impact factor: 12.969

Review 5.  DNA content and other factors associated with ten-year survival after resection of pancreatic carcinoma.

Authors:  D C Allison; S Piantadosi; R H Hruban; W C Dooley; E K Fishman; C J Yeo; K D Lillemoe; H A Pitt; P Lin; J L Cameron
Journal:  J Surg Oncol       Date:  1998-03       Impact factor: 3.454

6.  Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group.

Authors:  S Pedrazzoli; V DiCarlo; R Dionigi; F Mosca; P Pederzoli; C Pasquali; G Klöppel; K Dhaene; F Michelassi
Journal:  Ann Surg       Date:  1998-10       Impact factor: 12.969

7.  Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy.

Authors:  D Henne-Bruns; I Vogel; J Lüttges; G Klöppel; B Kremer
Journal:  Hepatogastroenterology       Date:  1998 May-Jun

Review 8.  Prognostic factors in ductal pancreatic cancer.

Authors:  C J Yeo; J L Cameron
Journal:  Langenbecks Arch Surg       Date:  1998-04       Impact factor: 3.445

9.  A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma.

Authors:  E M Jaffee; R Abrams; J Cameron; R Donehower; M Duerr; J Gossett; T F Greten; L Grochow; R Hruban; S Kern; K D Lillemoe; S O'Reilly; D Pardoll; H A Pitt; P Sauter; C Weber; C Yeo
Journal:  Hum Gene Ther       Date:  1998-09-01       Impact factor: 5.695

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  219 in total

1.  Duodenal adenocarcinoma: clinicopathologic analysis and implications for treatment.

Authors:  George A Poultsides; Lyen C Huang; John L Cameron; Richard Tuli; Leslie Lan; Ralph H Hruban; Timothy M Pawlik; Joseph M Herman; Barish H Edil; Nita Ahuja; Michael A Choti; Christopher L Wolfgang; Richard D Schulick
Journal:  Ann Surg Oncol       Date:  2011-12-14       Impact factor: 5.344

2.  Extended pancreatic resections and lymphadenectomy: An appraisal of the current evidence.

Authors:  Shailesh V Shrikhande; Savio G Barreto
Journal:  World J Gastrointest Surg       Date:  2010-02-27

3.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

4.  Changes in connexin43 expression and localization during pancreatic cancer progression.

Authors:  Joell L Solan; Sunil R Hingorani; Paul D Lampe
Journal:  J Membr Biol       Date:  2012-06-23       Impact factor: 1.843

5.  Postoperative Changes in Body Composition After Pancreaticoduodenectomy Using Multifrequency Bioelectrical Impedance Analysis.

Authors:  Manabu Mikamori; Atsushi Miyamoto; Tadafumi Asaoka; Sakae Maeda; Naoki Hama; Kazuyoshi Yamamoto; Motohiro Hirao; Masataka Ikeda; Mitsugu Sekimoto; Yuichiro Doki; Masaki Mori; Shoji Nakamori
Journal:  J Gastrointest Surg       Date:  2015-12-21       Impact factor: 3.452

Review 6.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 7.  Indications for staging laparoscopy in pancreatic cancer.

Authors:  Antonella De Rosa; Iain C Cameron; Dhanwant Gomez
Journal:  HPB (Oxford)       Date:  2015-11-18       Impact factor: 3.647

Review 8.  Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?

Authors:  H G Smeenk; T C K Tran; J Erdmann; C H J van Eijck; J Jeekel
Journal:  Langenbecks Arch Surg       Date:  2004-05-14       Impact factor: 3.445

9.  Pancreatic anastomotic leakage after pancreaticoduodenectomy in 1,507 patients: a report from the Pancreatic Anastomotic Leak Study Group.

Authors:  Kaye M Reid-Lombardo; Michael B Farnell; Stefano Crippa; Matthew Barnett; George Maupin; Claudio Bassi; L William Traverso
Journal:  J Gastrointest Surg       Date:  2007-08-21       Impact factor: 3.452

10.  Main-duct intraductal papillary mucinous neoplasms of the pancreas: clinical predictors of malignancy and long-term survival following resection.

Authors:  Roberto Salvia; Carlos Fernández-del Castillo; Claudio Bassi; Sarah P Thayer; Massimo Falconi; William Mantovani; Paolo Pederzoli; Andrew L Warshaw
Journal:  Ann Surg       Date:  2004-05       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.